Monthly Industry Report – Feb. 2025

The monthly Industry Report in reply-all shares a selection of news featuring UPMC Enterprises, our portfolio companies, and partnerships from the past month.

This edition, which stretches back into December, features stories about Abridge partnering with Mayo Clinic, Avista naming a Board Chairman, and many others.

UPMC Enterprises

• UPMC Enterprises backs several new companies | Pittsburgh Business Times 

Abridge

• Mayo Clinic picks Abridge for clinical generative AI after rigorous trials | Becker’s Healthcare 

Arrive Health

• Arrive Health, in partnership with AWS and a leading Integrated Delivery Network, Launches Innovative Generative AI-Powered Solution to Accelerate Medication Access | PR Newswire

Avista Therapeutics

• Avista Therapeutics Appoints Steven Altschuler, MD, as Chairman of the Board of Directors | PR Newswire 

BrainCheck

• Improving Early Detection of Cognitive Impairment and Dementia | Milken Institute 

Elektra Health

• From Conversation to Action: Advancing Equity & Access in Menopause Care in 2025 & Beyond | Elektra Health 

eVisit

• eVisit Awarded 2025 Best in KLAS for Virtual Care Platforms (Non-EHR) for Second Consecutive Year | PR Newswire

Ouro Medicines

• Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases | Ouro Medicines 

Realyze Intelligence

• Carta Healthcare to Power Oncology Research and Clinical Trials with Acquisition of Realyze Intelligence, a UPMC Enterprises Company | Healthcare IT Today 

Sempre Health

• Building and Scaling a Platform Business in Health Care | ScienceDirect 

SparingVision

• SparingVision advances PRODYGY trial into Phase II following positive DSMB recommendation | SparingVision 

Spark Pediatrics

• Spark Pediatrics Earns New Investment to Transform Pediatric Access to Skilled Nursing Through PPEC | Spark Pediatrics 

Sudo Biosciences

• Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550 | Sudo Biosciences 

Ultromics

• CMS Updates Final Outpatient Clinical APC Rule for Ultromics’ EchoGo® Heart Failure | Ultromics 

WHAM

• WHAM Launches First-of-its-Kind Women’s Health Investment Collaborative | FemTech Insider